Clinical trials
Early Breast Cancer clinical trials
Below are recruiting early breast cancer clinical trials, each written for real people, not researchers. We’re tracking 430 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05928429Recruiting
Cold treatment to prevent nerve pain from weekly paclitaxel
This trial tests whether cryotherapy (cooling the hands/feet during chemo) can prevent or lessen nerve pain caused by paclitaxel in people with early breast cancer. It may help you stay more comfortable and function better during treatment.
CopenhagenAges 18 years+ - NCT07647328RecruitingPhase 3
Camizestrant and ribociclib for advanced hormone-receptor-positive breast cancer
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
Duarte, CaliforniaAges 18–130 - NCT06629896Recruiting
Comparing contrast mammogram vs MRI for high-risk breast cancer surveillance
This trial compares two advanced imaging methods—contrast-enhanced mammography and MRI—to see which is better for detecting breast cancer early in women at high risk. If you are at high risk and have not had breast cancer before, this study could help guide your future screening.
Reggio Emilia, Italy/Reggio EmiliaAges 35–60 - NCT06462053RecruitingPhase 2
Short radiotherapy plus chemo and immunotherapy for early low rectal cancer
This study is testing whether a short course of radiation combined with chemotherapy and an immunotherapy drug works better than the standard longer radiation and chemotherapy for early-stage rectal cancer that is low in the rectum. The goal is to see if this shorter treatment can help patients avoid surgery or have a better outcome.
ShanghaiAges 18–75 - NCT04158843Recruiting
Local surgery vs comfort treatment for limited breast cancer spread
This trial compares a more direct local treatment (targeting a small, limited spot) versus a comfort-focused palliative approach for breast cancer that has spread only to one side of the upper arm bone or breastbone area. It aims to see which approach works better while keeping side effects manageable.
Hangzhou, ZhejiangAges 18–75 - NCT07395336RecruitingPhase 2
Elacestrant and exemestane for HR+/HER2- breast cancer that has spread
This trial tests combining elacestrant (a new hormone therapy) with exemestane (a standard hormone therapy) for people whose HR+/HER2- breast cancer has spread and who have already tried a CDK4/6 inhibitor with anastrozole or letrozole. It may help if your tumor shows certain activity on a special PET scan.
Milan, ItalyAges 18 years+ - NCT07104266RecruitingPhase 2
Celecoxib for early triple-negative breast cancer
This research study tests whether adding a drug called celecoxib (an anti-inflammatory pill) can help treat early-stage triple-negative breast cancer after surgery, before or during radiation therapy. You may be eligible if your cancer was removed cleanly and you do not have other health issues like stomach ulcers, kidney problems, or a history of allergic reactions to certain pain relievers.
Sherbrooke, QuebecAges 18 years+ - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04965064RecruitingPhase 2
Neratinib plus capecitabine for HER2-negative breast cancer brain mets
This study tests whether neratinib plus capecitabine can slow or shrink breast cancer that has spread to the brain. It is for people whose cancer shows an “overactive HER2 signal” on a specific tumor test, even though their cancer is labeled HER2-negative.
Rochester, New YorkAges 18 years+ - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06046365Recruiting
Early detection of arm swelling after breast cancer surgery
This trial tests a new way to measure arm swelling (lymphedema) early in women who have had or will have breast cancer surgery. It aims to catch swelling sooner so treatment can start faster.
Kaohsiung CityAges 20–80 - NCT07672392Recruiting
Exercise after breast reconstruction surgery
This trial tests whether a structured exercise program after DIEP flap breast reconstruction helps improve physical fitness compared to standard care. It may help women recover strength and well-being after surgery.
Beaumont, DublinAges 18 years+ - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT04800393Recruiting
Breast surgery anesthesia and its effects on immunity and survival
This study compares two ways of giving anesthesia during breast cancer surgery to see how they affect the immune system and outcomes after surgery. It may help identify which anesthesia approach is better for people like you having early-stage, operable breast cancer surgery.
MoscowAges 45–74 - NCT06341621RecruitingPhase 3
Skipping chemo for ER+/HER2- breast cancer with 1–3 positive nodes
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
ShanghaiAges 18–80 - NCT06738654Recruiting
Robotic breast-conserving surgery through the armpit for early-stage breast cancer
This trial tests a new robotic technique for removing early-stage breast cancer through the armpit, leaving no scar on the chest. It may be an option for women who want to keep their breast shape and avoid visible scarring.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT06595147Recruiting
Exercise for heart health in breast cancer survivors
This study tests if a 12-week exercise program improves heart health in women over 60 who have finished treatment for early-stage breast cancer. You will be placed in either an aerobic exercise group or a stretching group to see which helps your heart more.
Edmonton, AlbertaAges 60 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Birmingham, AlabamaAges 18–60 - NCT06992336RecruitingPhase 2
Circulating tumor DNA guided extra treatment for early triple-negative breast cancer
This trial tests whether using a blood test to detect leftover cancer DNA after initial treatment can help doctors decide if extra therapy is needed for people with early triple-negative breast cancer. It aims to improve outcomes for those with remaining disease after neoadjuvant therapy.
Guangzhou, GuangodngAges 18–70 - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06878625RecruitingPhase 2
Trop-2 drug combo for advanced triple-negative breast cancer
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
Tianjin, Tianjin MunicipalityAges 18–70 - NCT07259226RecruitingPhase 2
Studying resistance to antibody-drug conjugates in advanced cancer
This study is for people with advanced breast, bladder, lung, or stomach cancer who are about to start treatment with a type of targeted therapy called an antibody-drug conjugate (ADC). The trial will collect tumor samples and blood to understand how cancers become resistant to these drugs and to find better ways to predict treatment success.
VillejuifAges 18 years+
Hear when a new Early Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for early breast cancer?
- Yes. Clin2 currently lists 430 recruiting early breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a early breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a early breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.